- In May 2024, Natera, Inc. launched a groundbreaking fetal RhD diagnostic using cell-free DNA (cfDNA) to detect RhD status early in pregnancy, as early as nine weeks. This innovation helps physicians manage care amidst a shortage of Rho(D) immune globulin (RhIg). The test identifies RhD variants and is unique for its SNP-based technique, addressing the needs of RhD-negative pregnant individuals and preventing potential fetal hemolytic illness caused by alloimmunization
- In February 2024, Hikma Pharmaceuticals introduced COMBOGESIC IV, a non-opioid intravenous pain treatment in the U.S., combining 1,000 mg of acetaminophen and 300 mg of ibuprofen. This novel solution offers pain relief without opioids and is indicated for mild to moderate pain, and in combination with opioids for moderate to severe pain. The drug provides a multimodal approach, enhancing pain management by integrating different mechanisms of action
- In October 2023, The U.S. FDA approved COMBOGESIC IV for intravenous administration to manage pain. It combines 1,000 mg acetaminophen with 300 mg ibuprofen, offering an effective, non-opioid pain relief option. The drug is indicated for mild to moderate pain relief and as an adjunct to opioid analgesics for managing moderate to severe pain. It aligns with the American Society of Anesthesiology’s multimodal pain management approach
- In March 2022, Butterfly Network, Inc. secured a USD 5 million grant from the Bill and Melinda Gates Foundation to improve maternal and fetal health in Sub-Saharan Africa. The funds will provide 1,000 healthcare workers in the region with Butterfly iQ+, a handheld, whole-body ultrasound device. This initiative aims to enhance diagnostic capabilities in underserved areas, contributing to better healthcare outcomes for mothers and infants
- In February 2022, Philips expanded its handheld ultrasound portfolio with Lumify, now featuring Pulse Wave Doppler for advanced hemodynamic assessments. This addition allows clinicians to assess blood flow across various diagnostic applications, including cardiology, vascular, abdominal, urology, obstetrics, and gynecology. Lumify with Pulse Wave Doppler enhances clinicians' ability to evaluate blood circulation, aiding in the management of a wide range of medical conditions in point-of-care settings
